Antibiotic Susceptibility of Aerobic and Facultative Anaerobic Gram-Negative Rods in Hong Kong and Implications on Usefulness of Ceftazidime-Avibactam and Ceftolozane-Tazobactam

被引:0
|
作者
Teng, Jade L. L. [1 ]
Chan, Elaine [1 ,2 ]
Li, Tsz Tuen [1 ,2 ]
Kwan, Tsz Ying [2 ]
Chan, Ka Fai [2 ]
Li, Wing Ho [1 ,2 ]
Tang, Viki W. K. [2 ]
Yeung, Man Lung [2 ,3 ,4 ,5 ,6 ]
Lau, Susanna K. P. [2 ]
Woo, Patrick C. Y. [2 ,7 ,8 ,9 ]
机构
[1] Univ Hong Kong, Fac Dent, Hong Kong, Peoples R China
[2] Univ Hong Kong, Li Ka Shing Fac Med, Sch Clin Med, Dept Microbiol, Hong Kong, Peoples R China
[3] Univ Hong Kong, Li Ka Shing Fac Med, State Key Lab Emerging Infect Dis, Hong Kong, Peoples R China
[4] Univ Hong Kong, Shenzhen Hosp, Dept Clin Microbiol & Infect Control, Shenzhen 518053, Peoples R China
[5] Univ Hong Kong, Li Ka Shing Fac Med, Carol Yu Ctr Infect, Hong Kong, Peoples R China
[6] Hong Kong Sci & Technol Pk, Ctr Virol Vaccinol & Therapeut, Hong Kong, Peoples R China
[7] Natl Chung Hsing Univ, Doctoral Program Translat Med, Taichung 402, Taiwan
[8] Natl Chung Hsing Univ, Dept Life Sci, Taichung 402, Taiwan
[9] Natl Chung Hsing Univ, iEGG & Anim Biotechnol Ctr, Taichung 402, Taiwan
来源
ANTIBIOTICS-BASEL | 2024年 / 13卷 / 09期
关键词
antibiotic susceptibility; ceftazidime-avibactam; ceftolozane-tazobactam; multidrug resistance; ESBL-producing Enterobacterales; KLEBSIELLA-PNEUMONIAE; EXTENDED-SPECTRUM; ENTEROBACTERIACEAE; CARBAPENEMASE; SURVEILLANCE;
D O I
10.3390/antibiotics13090802
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Due to the increasing resistance of aerobic and facultative anaerobic Gram-negative rods, ceftazidime-avibactam and ceftolozane-tazobactam have been launched in the market in the last few years. In this study, we analyzed the susceptibility pattern of the major aerobic and facultative anaerobic Gram-negative rods in Hong Kong for ceftazidime-avibactam, ceftolozane-tazobactam, four other broad-spectrum antibiotics commonly used in Hong Kong and colistin. For 300 isolates collected from January to December 2021, non-ESBL-producing Enterobacterales, ESBL-producing Enterobacterales and Pseudomonas aeruginosa were highly susceptible to ceftazidime-avibactam (all 100%) and ceftolozane-tazobactam (98.7%, 99.7% and 94.3%). For 32 archived ESBL-producing Klebsiella pneumoniae isolates collected between January 2014 and March 2023, all were susceptible to ceftazidime-avibactam and ceftolozane-tazobactam. For 101 archived carbapenemase-producing Enterobacterales, their susceptibilities to ceftazidime-avibactam and ceftolozane-tazobactam varied depending on the type of carbapenemase produced. Both had high activities against OXA-producing strains (97.1% and 76.5%, respectively) but were 100% resistant for NDM-producing and NDM+OXA-producing strains. All KPC-producing strains were susceptible to ceftazidime-avibactam but resistant to ceftolozane-tazobactam. Ceftazidime-avibactam and ceftolozane-tazobactam are good alternatives for the management of infections caused by ESBL-producing Enterobacterales and selective strains of carbapenemase-producing Enterobacterales in Hong Kong.
引用
收藏
页数:13
相关论文
共 35 条
  • [21] Susceptibility of Meropenem-Resistant and/or Carbapenemase-Producing Clinical Isolates of Enterobacterales (Enterobacteriaceae) and Pseudomonas aeruginosa to Ceftazidime-Avibactam and Ceftolozane-Tazobactam as Assessed by In Vitro Testing Methods
    Cortazzo, Venere
    Posteraro, Brunella
    Menchinelli, Giulia
    Liotti, Flora Marzia
    D'Inzeo, Tiziana
    Fiori, Barbara
    Luzzaro, Francesco
    Sanguinetti, Maurizio
    Spanu, Teresa
    ANTIBIOTICS-BASEL, 2022, 11 (08):
  • [22] Clinical outcomes of intensive care unit patients infected with multidrug-resistant gram-negative bacteria treated with ceftazidime/avibactam and ceftolozane/tazobactam
    Neves, Camila Soares
    Moura, Libia Cristina Rocha Vilela
    Lima, Jailton Lobo Da Costa
    Maciel, Maria Amelia Vieira
    BRAZILIAN JOURNAL OF MICROBIOLOGY, 2024, 55 (01) : 333 - 341
  • [23] Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019
    Karlowsky, James A.
    Lob, Sibylle H.
    Khan, Aaron
    Chen, Wei-Ting
    Woo, Patrick C. Y.
    Seto, Wing Hong
    Ip, Margaret
    Leung, Stanley
    Wong, Queenie W-L
    Chau, Rene W. Y.
    DeRyke, C. Andrew
    Young, Katherine
    Motyl, Mary R.
    Sahm, Daniel F.
    JOURNAL OF MEDICAL MICROBIOLOGY, 2022, 71 (04)
  • [24] Activity of ceftolozane/tazobactam, imipenem/relebactam and ceftazidime/avibactam against clinical Gram-negative isolates-SMART United States 2019-21
    Karlowsky, James A.
    Lob, Sibylle H.
    Bauer, Karri A.
    Esterly, John
    Siddiqui, Fakhar
    Young, Katherine
    Motyl, Mary R.
    Sahm, Daniel F.
    JAC-ANTIMICROBIAL RESISTANCE, 2023, 6 (01):
  • [25] Meta-analysis of Clinical Outcomes Using Ceftazidime/Avibactam, Ceftolozane/Tazobactam, and Meropenem/Vaborbactam for the Treatment of Multidrug-Resistant Gram-Negative Infections
    Wilson, Geneva M.
    Fitzpatrick, Margaret
    Walding, Kyle
    Gonzalez, Beverly
    Schweizer, Marin L.
    Suda, Katie J.
    Evans, Charlesnika T.
    OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (02):
  • [26] Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms
    Khan, Ayesha
    Erickson, Samuel G.
    Pettaway, Cedric
    Arias, Cesar A.
    Miller, William R.
    Bhatti, Micah M.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (11)
  • [27] CEFTAZIDIME-AVIBACTAM FOR THE TREATMENT OF INFECTIONS DUE TO AEROBIC GRAM-NEGATIVE ORGANISMS IN PATIENTS WITH LIMITED TREATMENT OPTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Guerreiro, R.
    Alarcao, J.
    Pinheiro, B.
    Borges, M.
    Silva Miguel, L.
    Ines, M.
    Costa, J.
    VALUE IN HEALTH, 2019, 22 : S641 - S641
  • [28] Ceftolozane/Tazobactam and Ceftazidime/Avibactam: An Italian Multi-center Retrospective Analysis of Safety and Efficacy in Children With Hematologic Malignancies and Multi-drug Resistant Gram-negative Bacteria Infections
    Perruccio, Katia
    D'Amico, Maria Rosaria
    Baretta, Valentina
    Onofrillo, Daniela
    Carraro, Francesca
    Calore, Elisabetta
    Muggeo, Paola
    Colombini, Antonella
    Zama, Daniele
    Meazza, Cristina
    Cesaro, Simone
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2022, 41 (12) : 994 - 996
  • [29] Combined Resistance to Ceftolozane-Tazobactam and Ceftazidime-Avibactam in Extensively Drug-Resistant (XDR) and Multidrug-Resistant (MDR) Pseudomonas aeruginosa: Resistance Predictors and Impact on Clinical Outcomes Besides Implications for Antimicrobial Stewardship Programs
    Meschiari, Marianna
    Orlando, Gabriella
    Kaleci, Shaniko
    Bianco, Vincenzo
    Sarti, Mario
    Venturelli, Claudia
    Mussini, Cristina
    ANTIBIOTICS-BASEL, 2021, 10 (10):
  • [30] Synergistic Activity of Cefiderocol in Combination with Piperacillin-Tazobactam, Fosfomycin, Ampicillin-Sulbactam, Imipenem-Relebactam and Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative Bacteria
    Palombo, Marta
    Bovo, Federica
    Amadesi, Stefano
    Gaibani, Paolo
    ANTIBIOTICS-BASEL, 2023, 12 (05):